View Exam | PowerPak

1. A 43-year old woman with moderate RA exhibits an inadequate response to methotrexate monotherapy. An anti-tumor necrosis factor (TNF) agent is added to her regimen. Three months later, it is determined that she is in remission. According to the treat-to-target approach, how often should she have her disease activity assessed now that she has achieved remission?

A. Monthly B. Every other month C. Every 3-6 months D. Every year

2. Which vaccine should NOT be administered to an RA patient receiving a bDMARD?

A. Hepatitis B B. Herpes zoster C. Influenza (intramuscular) D. Pneumococcal

3. Which agent is an anti-TNF therapy?

A. Abatacept B. Certolizumab C. Rituximab D. Tocilizumab

4. Which statement accurately describes the differences between tofacitinib and baricitinib?

A. Tofacitinib is an oral agent while baricitinib is injected subcutaneously B. In clinical trials, tofacitinab treated patients with RA achieved remission while this was not observed with baricitinib C. Tofacitinib is FDA approved for RA while baricitinib is FDA approved for psoriasis D. Baricitinib and tofacitinib target different members of the JAK family

5. According to data from patient registries and the comparative effectiveness report from the Agency for Healthcare Research and Quality (AHRQ) what risk is increased with anti-TNF therapy use?

A. Lymphoma B. Non-melanoma skin cancers C. Non-small-cell lung carcinoma D. Progressive multifocal leukoencephalopathy

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

2. Which vaccine should NOT be administered to an RA patient receiving a bDMARD?

3. Which agent is an anti-TNF therapy?

4. Which statement accurately describes the differences between tofacitinib and baricitinib?

5. According to data from patient registries and the comparative effectiveness report from the Agency for Healthcare Research and Quality (AHRQ) what risk is increased with anti-TNF therapy use?

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

2. Which vaccine should NOT be administered to an RA patient receiving a bDMARD?

3. Which agent is an anti-TNF therapy?

4. Which statement accurately describes the differences between tofacitinib and baricitinib?

5. According to data from patient registries and the comparative effectiveness report from the Agency for Healthcare Research and Quality (AHRQ) what risk is increased with anti-TNF therapy use?

« Return to Activity

Customers who Purchased
this Activity also Purchased